Health

Medicare starts coverage review for Biogen Alzheimer’s drug – STAT


Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the Pharmalot campus, where things have settled down now that the short person has left for gainful employment and the official mascot has assumed his formal snoozing position. As for us, we are dutifully concocting a few needed cups of stimulation as we dig in for another busy day. No doubt, you can relate. So time to get cracking. As always, we have assembled some items of interest. So hoist your own cup to a successful day, and drop us a line when something interesting arises. …

The Centers for Medicare & Medicaid Services announced plans to start a process that could limit access to the controversial new Alzheimer’s drug from Biogen (BIIB) — the first signals from the agency about what will be an enormously consequential decision for Biogen, the Medicare program itself, and people with the disease, STAT writes. The process, called a National Coverage Determination analysis, ensures that coverage for the drug is uniform across the country instead of leaving decisions to regional contractors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED


Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button